The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
about
Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and CancerTissue- and Serum-Associated Biomarkers of Hepatocellular CarcinomaGlypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinomaCurrent status and perspectives of immune-based therapies for hepatocellular carcinomaCurrent concepts in the immunohistochemical evaluation of liver tumorsSystemic therapy of hepatocellular carcinoma: current status and future perspectivesAdvances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinGPC-3 in hepatocellular carcinoma: current perspectivesGlypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal neurogenesis.Liver metastasis from hepatoid adenocarcinoma of the esophagus mimicking hepatocellular carcinoma.Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.Liverome: a curated database of liver cancer-related gene signatures with self-contained context informationExpression of glypican 3 in placental site trophoblastic tumor.Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library.Glypican-3: a new target for cancer immunotherapy.Histopathology of hepatocellular carcinomaGlypican-1 regulates anaphase promoting complex/cyclosome substrates and cell cycle progression in endothelial cells.Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules.Seminal vesicle metastasis after partial hepatectomy for hepatocellular carcinomaMolecular pathology of hepatic neoplasms: classification and clinical significance.The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature reviewExpression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liverTherapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges.Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation.Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma.Glypican-3 antibodies: a new therapeutic target for liver cancer.Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.Pathology for the HPB Surgeon.An Overview of Biomarkers and Molecular Signatures in HCC.Cytokeratin 20-positive hepatocellular carcinoma.Assessment of stromal invasion for correct histological diagnosis of early hepatocellular carcinoma.Impaired autophagy response in human hepatocellular carcinoma.
P2860
Q26740617-996E06D9-8048-495E-B0D6-72E690CCB720Q26743361-ACD49637-D24A-4F3F-9DA9-E09E093F3CCAQ26772321-C40475C6-6732-43D8-96B0-6AF049EC48E3Q26772326-189F0C63-EB74-47B2-90E4-2EAAF1220A2FQ26864205-F44B9F8A-38CE-4D61-8F0A-25A251D5CBF2Q26865844-A53500C7-F4C6-4E87-AB58-8775D22DBC8BQ27015134-F13A2772-9E92-465A-8ABB-6EAD6CF2DBAAQ28066774-8A1C24B5-01EE-46A2-9997-AA1057D8B889Q33601245-06974C14-C772-4728-AA27-DEB407D60CC4Q33726816-9DB32003-297F-4FD3-9943-2041C0DE4C1FQ33914169-538B3257-1A23-4497-B3FC-A5F68C5E6D33Q34173509-BFDA6372-7AEE-4361-8CE7-2E11CB835B66Q34199179-7BA1B520-D90C-47D8-87F8-CA9436EBD8EAQ34260503-7CEAB67E-048D-499F-AB66-8EFCFA43B79EQ34543102-137433D8-01FE-4D1B-9C35-01299314353FQ34552007-7F34E39C-5D77-499D-AC75-208811F0D7B8Q34770477-37981732-90C6-4B35-BE78-9C2A20DDD67CQ34809541-22BA126B-9810-4598-90C0-86D4B46A9E9DQ34818437-36FD9EDE-F80B-4E0A-9F61-833F7830112BQ34954493-84B36EC4-A1DC-4014-A6E6-23369AF6D6A8Q36197579-D7563247-52FA-4DFE-9082-280E45B894A6Q36561628-2FB8A26F-08E7-4336-B6E1-0DC23136CF36Q36598885-9BE32683-01F4-4DB9-BF0A-A7B42389B2A4Q36712597-B5DA477B-E6CB-42E2-9981-E0B090F72192Q36716630-071802A9-3938-4CE5-915B-BF102B12EA9EQ36787608-39B28BC0-7CE3-4264-81BE-148C4BB80438Q36802501-0FFA097A-FE9B-45D7-9762-E005BD9D6B17Q37031710-7106F49D-B47C-4201-88E8-3BAA34CE770AQ37278475-53571240-892B-40F7-89E2-240D28C592E8Q37299042-605A7E63-E093-4402-88C8-6AC8A067356EQ37538453-5F0EF7E9-D320-45C2-9FE1-8E351982AE94Q37625736-00B2E9B0-4789-40E6-970E-202BA661BB93Q37625957-C22A3476-C932-43C9-AA56-96CA09632989Q37685728-2F19B133-F48E-4AD9-B50A-5DAFF902F7B8Q37688462-FD75F948-5226-4387-88AA-7F3C3CA44DF1Q38078346-F8E94F3E-9C01-49C6-A926-7B0A5C2488D1Q38166571-25868A43-16E8-434B-B995-0B1420030CC7Q38313857-E84CE1F7-F2EF-46C6-9540-D2F17159D940Q38367782-D81D1683-39F5-4A54-B5DB-EB9EF15805B6Q38393661-8A89A7E5-BD57-4003-88DA-73672B99D55B
P2860
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The glypican 3 oncofetal prote ...... for hepatocellular carcinoma.
@en
type
label
The glypican 3 oncofetal prote ...... for hepatocellular carcinoma.
@en
prefLabel
The glypican 3 oncofetal prote ...... for hepatocellular carcinoma.
@en
P2093
P2860
P1433
P1476
The glypican 3 oncofetal prote ...... for hepatocellular carcinoma.
@en
P2093
Akira Watanabe
Hiroko Iwanari
Hiroyuki Aburatani
Junji Shibahara
Ken-Ichi Ohashi
Masashi Fukayama
Masatoshi Makuuchi
Masaya Mori
Michiyo Hishinuma
Naoko Yamauchi
P2860
P2888
P304
P356
10.1038/MODPATHOL.3800436
P577
2005-12-01T00:00:00Z
P5875
P6179
1027594159